OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Falkson on the Potential to De-Escalate Chemotherapy in HER2+ Breast Cancer

November 12th 2021

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

November 12th 2021

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Yu on the Utility of Enfortumab Vedotin in Metastatic Urothelial Cancer

November 12th 2021

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer. 

Dr. Grivas on Attempts to Improve Upon Chemotherapy in Urothelial Cancer

November 12th 2021

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

Dr. Vaidya on Advances in the Management of Endometrial Cancer

November 11th 2021

Ami P. Vaidya, MD, discusses advances in the management of endometrial cancer.

Dr. Michalski on the Goals ASTRO in Radiation Oncology

November 11th 2021

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

Dr. Ivanick on the Diagnostic Role of Interventional Pulmonologists in Lung Cancer

November 11th 2021

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Dr. Rimawi on Future Research Directions in Metastatic HER2+ Breast Cancer

November 11th 2021

Mothaffar Fahed Rimawi, MD, discusses future research directions in metastatic HER2-positive breast cancer. 

Dr. Yentz on Unmet Needs in Metastatic RCC

November 11th 2021

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Palmbos on the Role of Chemoimmunotherapy in Bladder Cancer

November 11th 2021

Phillip Palmbos, MD, PhD, discusses the role of chemoimmunotherapy in patients with bladder cancer.

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer

November 11th 2021

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Dr. Langer on the Need for Reflex Testing in NSCLC

November 10th 2021

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Dr. Hanna on the Efficacy of Tipifarnib in HRAS-Mutated Head and Neck Cancer

November 10th 2021

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

November 10th 2021

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

Dr. Bordoni on the Utility of Adjuvant Osimertinib in ​EGFR-Mutant Lung Cancer

November 10th 2021

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

Dr. Saif on the Rationale to Utilize PARP Inhibitors in BRCA+ Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

November 10th 2021

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.

Dr. Kimmick on the Results of the ATEMPT Trial in Early-Stage HER2+ Breast Cancer

November 9th 2021

Gretchen G. Kimmick, MD, MS, discusses the results of the phase 2 ATEMPT trial in early-stage HER2-positive breast cancer

Dr. Stephens Discusses Optimizing Treatment Selection in CLL

November 9th 2021

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.

Dr. Mukherjee on Determining When to Initiate Immunotherapy in Gastroesophageal Cancer

November 9th 2021

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

NEXT PAGE
PREVIOUS PAGE